You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 7, 2024

Claims for Patent: 8,039,010

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,039,010

Title:	Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
Abstract:	A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.
Inventor(s):	Trogden; John T. (Anaheim, CA), Lyons; Robert T. (Laguna Hills, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	11/556,503
Patent Claims:	1. A sustained release, biodegradable intraocular implant comprising a) about 70-85% by weight of a biodegradable polymeric carrier, wherein the biodegradable polymeric carrier is a poly-lactide-co-glycolide (PLGA) co-polymer; b) about 10-20% by weight of a water soluble therapeutic agent, wherein the therapeutic agent is an inhibitor of vascular endothelial growth factor (VEGF) selected from the group consisting of ranibizumab, bevacizumab, mixtures of ranibizumab and bevacizumab, pegaptanib, and an siRNA molecule; and c) about 5-10% by weight of a long chain fatty alcohol comprising from between 10 to 40 carbon atoms; wherein a therapeutically effective amount of the therapeutic agent is released from the biodegradable intraocular implant for at least one week after the intraocular implant is placed in the eye. 2. The intraocular implant of claim 1, wherein the long chain fatty alcohol is selected from the group consisting of capric alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, palmitoleyl alcohol, stearyl alcohol, isostearyl alcohol, elaidyl alcohol, oleyl alcohol, linoleyl alcohol, polyunsaturated elaidolinoleyl alcohol, polyunsaturated linolenyl alcohol, elaidolinolenyl alcohol, polyunsaturated ricinoleyl alcohol, arachidyl alcohol, behenyl alcohol, erucyl alcohol, lignoceryl alcohol, ceryl alcohol, montanyl alcohol, cluytyl alcohol, myricyl alcohol, melissyl alcohol, and geddyl alcohol. 3. A method for treating an ocular condition, the method comprising the step of intraocular placement of a sustained release, biodegradable intraocular implant according to claim 1. 4. The method of claim 3, wherein the step of intraocular placement is carried out using an intraocular injector. 5. The method of claim 3, wherein the ocular condition is selected from the group consisting of uveitis, macular edema, macular degeneration, proliferative retinopathy, diabetic retinopathy, retinitis pigmentosa and glaucoma. 6. The intraocular implant of claim 1, wherein said long chain fatty alcohol is selected from the group consisting of 1-hexadecanol, 1-octadecanol, and 1-eicosanol. 7. The intraocular implant of claim 1, wherein said long chain fatty alcohol is a saturated straight chain alcohol 16 to 26 carbon atoms in length. 8. The intraocular implant of claim 1, wherein said long chain fatty alcohol is 1-eicosanol.

Details for Patent 8,039,010

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2039-03-29
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2039-03-29
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2039-03-29
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2039-03-29
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.